News & Updates

A stepwise dual antiplatelet therapy (DAPT) de-escalation strategy among patients with acute coronary syndrome (ACS) who could be treated by paclitaxel-coated balloons without stents demonstrates noninferiority to the standard 12-month DAPT for all net adverse clinical events, according to a study.

Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.

Patients with symptomatic peripheral artery disease and type 2 diabetes see notable improvements in their walking capacity and quality of life with once-weekly semaglutide injections in the phase 3b STRIDE study.